NCT04596696View on ClinicalTrials.gov

Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam

PHASE3CompletedINTERVENTIONAL

Enrollment

360

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

December 30, 2018

Study Completion Date

June 30, 2019

Conditions

Rotavirus Gastroenteritis

Interventions

BIOLOGICAL

Rotavac

Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.

Trial Locations (1)

Unknown

Vietnam Military Medical University Hospital, Hanoi

All Listed Sponsors

lead

Bharat Biotech International Limited

INDUSTRY

NCT04596696 - Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam | Biotech Hunter | Biotech Hunter